Financials
Financial year 2025
Worth noting
- Little cash and receivables against the short-term debts.
Revenue
€ 3,642.1 million
▲ 2% vs 2024
Profit
Growing€ 113.8 million
▲ 1245% vs 2024
Debts
Normal€ 5,609.1 million
▲ 17% vs 2024
UCB BIOPHARMA from Anderlecht, company number BE0543573053, closed financial year 2025 with a result of € 113.8 million after tax. For that financial year UCB BIOPHARMA recorded revenue of € 3,642.1 million and equity of € 1,175 million. Compared with financial year 2024, the result moved from € 8.5 million to € 113.8 million. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
What happened at UCB BIOPHARMA?
What happened at UCB BIOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 113.8 million (▲ 1245% vs 2024). Source: NBB ↗
- Alistair HENRY became a director. NBB
- Denelle J. WAYNICK JOHNSON became a director. NBB
- New establishment in Leuven. KBO
- Sandrine DUFOUR became a director. NBB
- Jean-Luc FLEURIAL became a director. NBB
- New establishment in Braine-l'Alleud. KBO
- New establishment in Anderlecht. KBO
In short
From € 510.4 million loss in 2021 to € 113.8 million profit in 2025.
Paid € 10.6 million in corporate taxes since 2021.
Best year ever: 2025, with € 113.8 million profit.
Pays suppliers within 106 days on average.
A new publication or filing at UCB BIOPHARMA? We notify you, reason included.
Follow UCB BIOPHARMANeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind UCB BIOPHARMA are Sandrine DUFOUR, Jean-Luc FLEURIAL, Alistair HENRY and Denelle J. WAYNICK JOHNSON. The shares are held by UCB Pharma SA (100%). It owns 41.1% of Farnia Biologics, 17.9% of ExeVir Bio and 4.4% of Grin Therapeutics, Inc. itself.
Directors
According to the 2025 annual accounts
since 2020
Jean-Luc FLEURIAL
Director
since 2017
since 2024
since 2023
Shareholders
100%
Participations
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Chemin du Foriest /
1420 Braine-l'Alleud
Active since 1 April 2014
Gaston Geenslaan 14
3001 Leuven
Active since 1 July 2021
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
UCB Belgium
U C B
UCB PHARMA same network
€ 4,622.6 million revenue · 2025
UCB Fipar same network
Fondation Emmanuel Janssen
+5 more
Details
- Company number
- 0543.573.053
- VAT number
- BE 0543.573.053
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB BIOPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 December 2013
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Speur- en ontwikkelingswerk op biotechnologisch gebied